Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04858256 · ClinicalTrials.gov registry record · Phase 2
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
A Phase 2 study of Lymphoproliferative Disorders and T-Cell Neoplasm, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 6
- Study locations
NCT04858256 is a Phase 2 study of Lymphoproliferative Disorders and T-Cell Neoplasm that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 100 participants, below the 231-participant average among 12 other Lymphoproliferative Disorders trials with a reported enrollment target (57% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT04858256, a Phase 2 study of Lymphoproliferative Disorders and T-Cell Neoplasm, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Conditions Studied
Interventions
- DRUG Pacritinib
Study Locations (6)
California
- City of Hope - Duarte
Florida
- Moffitt Cancer Center - Tampa
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
North Carolina
- Duke Cancer Institute - Durham
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04858256
The ClinicalTrials.gov registry entry for NCT04858256 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 12 other Lymphoproliferative Disorders trials with a reported enrollment target (57% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoproliferative Disorders appearing as the primary indexed condition, and to 1 intervention - of which Pacritinib is the first listed.
NCT04858256 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT04858256 about?
NCT04858256 is a clinical study titled "Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms". The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
What is the current status of trial NCT04858256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-03-29. Estimated completion is 2028-11.
What conditions does trial NCT04858256 study?
This clinical trial studies the following conditions: Lymphoproliferative Disorders, T-Cell Neoplasm.
What interventions are being tested in trial NCT04858256?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT04858256?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04858256 being conducted?
This trial has 6 study locations across California, Florida, Michigan, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoproliferative Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
ACTIVE NOT RECRUITING · Phase 2
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.